Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors
Phase 1
18 Years
65 Years
18 Years
65 Years
Not Enrolling
Both
Neoplasms
Both
Neoplasms
Trial Information
Safety and Tolerability Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Combination With Docetaxel in Advanced Solid Tumors
Inclusion Criteria
Inclusion:
- Male or Female
- Measurable or evaluable disease
- No more than 2 prior chemotherapy regimens.
- Age greater than or equal to 18.
- Karnofsky Performance Status greater than or equal to 70%.
- Meets protocol requirements for specified laboratory values.
- No manifestations of a malabsorption syndrome.
- Written informed consent and cooperation of patient
- Appropriate use of effective contraception if of child-bearing potential.
Exclusion:
- Acute or chronic leukemia or multiple myeloma.
- Evidence of 2 or more active malignancies, expect for in situ or adequately treated
basal or squamous cell skin cancer.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Adverse Events
Authority:
United States: Food and Drug Administration
Study ID:
P01964
NCT ID:
NCT00040547
Start Date:
June 2001
Completion Date:
Related Keywords:
- Neoplasms
- Cancer-Advanced Solid Tumors
- Neoplasms
Name | Location |
|---|
